Table 2. Summary of 1,000 Simulation Results for Dose and Risk Probabilities during Urine Collection and Struvite Production^ba.

study component	pathogen	study participant/study day	total time evaluated (s)	number of facemask/mouth contacts observed	number of nonzero doses simulated	average of median single doses, DP(tj) [average of lower 95% CI, average of upper 95% CI]	average of median single risks [average lower 95% CI, average upper 95% CI]	cumulative risk [lower 95% CI, upper 95% CI]
urine collection	rotavirus	P1/D1	6290	70/0	67	4.0 × 10-1 [3.2 × 10-2, 1.4]	1.5 × 10-1 [1.8 × 10-2, 3.0 × 10-1]	6.5 × 10-1 [3.6 × 10-1, 7.4 × 10-1]
		P2/D1	6429	2/0	1	2.7 × 10-1 [1.9 × 10-2, 1.1]	1.2 × 10-1 [1.1 × 10-2, 2.8 × 10-1]	1.2 × 10-1 [1.1 × 10-2, 2.8 × 10-1]
		P1/D2	12012	126/3	111	2.8 × 10-1 [2.2 × 10-2, 9.9 × 10-1]	1.1 × 10-1 [1.3 × 10-2, 2.4 × 10-1]	6.6 × 10-1 [3.9 × 10-1, 7.6 × 10-1]
		P3/D2	11956	95/8	86	2.4 × 10-1 [1.9 × 10-2, 8.6 × 10-1]	9.5 × 10-2 [1.1 × 10-2, 2.0 × 10-1]	6.3 × 10-1 [3.3 × 10-1, 7.3 × 10-1]
		P2/D3	8885	60/0	60	4.3 × 10-1 [3.6 × 10-2, 1.5]	1.6 × 10-1 [2.0 × 10-2, 3.1 × 10-1]	6.5 × 10-1 [3.7 × 10-1, 7.4 × 10-1]
	Shigella spp.	P1/D1	6290	70/0	67	7.8 × 10-1 [6.2 × 10-2, 2.7]	1.8 × 10-3 [1.4 × 10-4, 6.0 × 10-3]	9.4 × 10-2 [9.3 × 10-3, 2.2 × 10-1]
		P2/D1	6429	2/0	1	4.5 × 10-1 [4.0 × 10-2, 1.8]	1.0 × 10-3 [9.1 × 10-5, 4.1 × 10-3]	1.0 × 10-3 [9.1 × 10-5, 4.1 × 10-3]
		P1/D2	12012	126/3	111	5.6 × 10-1 [4.5 × 10-2, 2]	1.3 × 10-3 [1.0 × 10-4, 4.4 × 10-3]	1.1 × 10-1 [1.1 × 10-2, 2.4 × 10-1]
		P3/D2	11956	95/8	86	4.6 × 10-1 [3.7 × 10-2, 1.6]	1.0 × 10-3 [8.5 × 10-5, 3.7 × 10-3]	7.5 × 10-2 [7.2 × 10-3, 1.9 × 10-1]
		P2/D3	8885	60/0	60	8.2 × 10-1 [6.5 × 10-2, 2.9]	1.8 × 10-3 [1.5 × 10-4, 6.4 × 10-3]	8.9 × 10-2 [8.6 × 10-3, 2.1 × 10-1]
struvite production	rotavirus	P1/D1	14537	64/NTb	61	2.8 × 10-2 [2.3 × 10-3, 1.1 × 10-1]	1.6 × 10-2 [1.3 × 10-3, 5.3 × 10-2]	3.4 × 10-1 [6.9 × 10-2, 5.1 × 10-1]
		P2/D1	14710	48/NTb	42	6.2 × 10-2 [5.0 × 10-3, 2.4 × 10-1]	3.3 × 10-2 [2.9 × 10-3, 1.0 × 10-1]	3.9 × 10-1 [9.6 × 10-2, 5.5 × 10-1]
		P1/D2	5776	14/NTb	14	6.0 × 10-2 [4.6 × 10-3, 2.5 × 10-1]	3.2 × 10-2 [2.7 × 10-3, 1.1 × 10-1]	2.4 × 10-1 [3.5 × 10-2, 4.3 × 10-1]
		P2/D2	7281	9/NTb	9	7.7 × 10-2 [6.1 × 10-3, 3.1 × 10-1]	4.1 × 10-2 [3.6 × 10-3, 1.3 × 10-1]	2.2 × 10-1 [3.0 × 10-2, 4.0 × 10-1]
	Shigella spp.	P1/D1	14537	64/NTb	61	6.1 × 10-2 [4.5 × 10-3, 2.3 × 10-1]	1.4 × 10-4 [1.0 × 10-5, 5.1 × 10-4]	8.3 × 10-3 [6.2 × 10-4, 2.9 × 10-2]
		P2/D1	14710	48/NTb	42	1.4 × 10-1 [1.1 × 10-2, 5.1 × 10-1]	3.1 × 10-4 [2.5 × 10-5, 1.1 × 10-3]	1.3 × 10-2 [1.0 × 10-3, 4.3 × 10-2]
		P1/D2	5776	14/NTb	14	1.4 × 10-1 [1.0 × 10-2, 5.4 × 10-1]	3.1 × 10-4 [2.3 × 10-5, 1.2 × 10-3]	4.3 × 10-3 [3.2 × 10-4, 1.6 × 10-2]
		P2/D2	7281	9/NTb	9	1.7 × 10-1 [1.4 × 10-2, 6.5 × 10-1]	4.0 × 10-4 [3.1 × 10-5, 1.5 × 10-3]	3.5 × 10-3 [2.8 × 10-4, 1.3 × 10-2]

^aSingle doses and risks refer to those encountered from a single hand-mouth contact. Cumulative risk is presented for each study participant workday.

^bNot Translated: for struvite production, facemask and mouth contacts were not distinguished during translation.